Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Aug 30;11(10):368.
doi: 10.21037/atm-23-839. Epub 2023 Mar 13.

Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond

Lanyi Nora Chen  1 , Richard D Carvajal  2
Affiliations
Editorial

Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond

Lanyi Nora Chen et al. Ann Transl Med. .
No abstract available

Keywords: Melanoma; adjuvant therapy; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-23-839/coif). RDC reports research funding to Columbia University from Amgen, Astellis, AstraZeneca, BioMed Valley, Bolt, Bristol-Myers Squibb, Corvus, Cstone, Foghorn, Ideaya, Immatics, Immunocore, InxMed, Iovance, Merck, Mirati, Novartis, Pfizer, Plexxikon, Regeneron, Roche/Genentech, received consulting fees from Alkermes, Bristol Myers Squibb, Castle Biosciences, Delcath, Eisai, Hengrui, Ideaya, Immunocore, InxMed, Iovance, Merck, Novartis, Oncosec, Pierre Fabre, PureTech Health, Regeneron, Sanofi Genzyme, Sorrento Therapeutics and Trisalus, payments or honoraria from PER, involved on Clinical/Scientific Advisory Boards for Celldex, Aura Biosciences, Chimeron and Rgenix, and received stock or stock options from Aura Biosciences, Chimeron, Rgenix. The other author has no conflicts of interest to declare.

Comment on

References

    1. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med 2018;378:1789-801. 10.1056/NEJMoa1802357 - DOI - PubMed
    1. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med 2017;377:1824-35. 10.1056/NEJMoa1709030 - DOI - PubMed
    1. Poklepovic AS, Luke JJ. Considering adjuvant therapy for stage II melanoma. Cancer 2020;126:1166-74. 10.1002/cncr.32585 - DOI - PMC - PubMed
    1. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:472-92. - PMC - PubMed
    1. Egger ME, Bhutiani N, Farmer RW, et al. Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes. Surgery 2016;159:1412-21. 10.1016/j.surg.2015.12.002 - DOI - PubMed